Moderna Stock Plummets 6.87% as Patent Settlement Drives 191st-Highest Trading Volume

Market Snapshot

On March 5, 2026, ModernaMRNA-- (NASDAQ: MRNA) experienced a significant decline in trading activity and share price. The stock closed down 6.87%, with a trading volume of $0.76 billion, reflecting a 41.03% drop compared to the previous day’s volume. This marked the 191st highest trading volume in the market, underscoring a sharp reduction in investor activity following a recent surge driven by news of a patent dispute settlement.

Key Drivers

The settlement of a long-standing legal dispute over lipid nanoparticle (LNP) technology used in Moderna’s mRNA vaccines emerged as the primary catalyst for short-term volatility. Moderna agreed to pay up to $2.25 billion to Arbutus Biopharma and Roivant subsidiary Genevant Sciences, resolving claims of patent infringement. The agreement includes an upfront $950 million payment in July 2026 and a contingent $1.3 billion payment contingent on the outcome of an appeal to the U.S. Court of Appeals for the Federal Circuit. This structure effectively caps Moderna’s liability at $2.25 billion, significantly lower than the $5 billion initially sought by the plaintiffs.

The resolution removed a major financial and legal overhang for Moderna, which had faced potential royalties on future mRNA vaccine sales. By securing a royalty-free, perpetual license to Genevant’s LNP technology, Moderna avoids ongoing cash outflows, preserving liquidity. The company now projects ending 2026 with $4.5–$5 billion in cash and access to $900 million via an existing credit facility. Analysts noted this outcome as a “successful dodged bullet,” with Leerink Partners’ Mani Foroohar highlighting investor relief over avoiding a “worst-case scenario” that could have strained Moderna’s balance sheet.

However, the contingent payment introduces uncertainty tied to the Federal Circuit’s interpretation of Section 1498 of the U.S. patent law, which governs government-contractor immunity. The court will determine whether Moderna’s pandemic-era government contracts shield it from patent infringement claims. A favorable ruling would negate the $1.3 billion payment, while an adverse decision could reduce Moderna’s cash reserves to as low as $3.2 billion by 2026, according to Bernstein analyst Courtney Breen. This appellate outcome also sets a legal precedent with broader implications for companies involved in federally funded projects, as highlighted by legal experts such as Duke University’s Arti Rai.

Investor sentiment shifted further with Moderna’s announcement of a positive European Medicines Agency opinion for its combination flu and COVID vaccine, targeting adults aged 50+. This, coupled with the settlement, redirected focus toward the company’s oncology pipeline, which analysts like William Blair’s Myles Minter deem critical for long-term growth. With multiple late-stage trials expected in 2026, Moderna’s ability to deliver robust data could mitigate near-term legal risks and reinvigorate investor confidence.

The stock’s intraday volatility—ranging from a 9% pre-market gain to a 6.87% close—reflects the dual impact of immediate legal resolution and lingering uncertainties. While the settlement alleviated fears of acute financial distress, the contingent payment and ongoing litigation with Pfizer and BioNTech (over mRNA technology patents) remain near-term headwinds. Moderna’s strategic pivot to oncology and infectious disease vaccines, combined with its strengthened liquidity position, positions it to navigate these challenges, though execution risks persist.